125 related articles for article (PubMed ID: 7604141)
21. Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine.
Wilens TE; Biederman J; Baldessarini RJ; Puopolo PR; Flood JG
J Am Acad Child Adolesc Psychiatry; 1992 Jul; 31(4):691-8. PubMed ID: 1644733
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine.
Britzi M; Perucca E; Soback S; Levy RH; Fattore C; Crema F; Gatti G; Doose DR; Maryanoff BE; Bialer M
Epilepsia; 2005 Mar; 46(3):378-84. PubMed ID: 15730535
[TBL] [Abstract][Full Text] [Related]
23. Hydroxydesipramine in the elderly.
Nelson JC; Atillasoy E; Mazure C; Jatlow PI
J Clin Psychopharmacol; 1988 Dec; 8(6):428-33. PubMed ID: 3235701
[TBL] [Abstract][Full Text] [Related]
24. Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine.
Spina E; Tomson T; Svensson JO; Faigle JW; Bertilsson L
Ther Drug Monit; 1988; 10(4):382-5. PubMed ID: 3201523
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes.
von Bahr C; Spina E; Birgersson C; Ericsson O; Göransson M; Henthorn T; Sjöqvist F
Biochem Pharmacol; 1985 Jul; 34(14):2501-5. PubMed ID: 4015690
[TBL] [Abstract][Full Text] [Related]
26. Effect of valpromide on the pharmacokinetics of carbamazepine-10, 11-epoxide.
Pisani F; Fazio A; Oteri G; Spina E; Perucca E; Bertilsson L
Br J Clin Pharmacol; 1988 May; 25(5):611-3. PubMed ID: 3136790
[TBL] [Abstract][Full Text] [Related]
27. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
[TBL] [Abstract][Full Text] [Related]
28. Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine.
Wilens TE; Biederman J; Baldessarini RJ; Puopolo PR; Flood JG
J Am Acad Child Adolesc Psychiatry; 1993 Jul; 32(4):798-804. PubMed ID: 8340301
[TBL] [Abstract][Full Text] [Related]
29. Effect of fluoxetine pretreatment on plasma and tissue concentrations of desipramine in rats.
Fuller RW; Perry KW
Res Commun Chem Pathol Pharmacol; 1989 Dec; 66(3):375-84. PubMed ID: 2609015
[TBL] [Abstract][Full Text] [Related]
30. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
Brøsen K; Gram LF
Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
[TBL] [Abstract][Full Text] [Related]
31. Hepatic metabolism of imipramine after prolonged administration of the drug to rats. An in vivo study.
Melzacka M; Danek L; Adamus A
Pol J Pharmacol Pharm; 1987; 39(4):379-86. PubMed ID: 3449809
[TBL] [Abstract][Full Text] [Related]
32. Effects of cimetidine on carbamazepine auto- and hetero-induction in man.
Macphee GJ; Thompson GG; Scobie G; Agnew E; Park BK; Murray T; McColl KE; Brodie MJ
Br J Clin Pharmacol; 1984 Sep; 18(3):411-9. PubMed ID: 6487479
[TBL] [Abstract][Full Text] [Related]
33. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
Brøsen K; Otton SV; Gram LF
Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
[TBL] [Abstract][Full Text] [Related]
34. Stable isotope coadministration methodology for the estimation of the fraction of imipramine metabolized to desipramine.
Sasaki Y; Shinohara Y; Baba S
J Pharm Sci; 1990 Feb; 79(2):96-8. PubMed ID: 2324970
[TBL] [Abstract][Full Text] [Related]
35. Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers.
Bedada SK; Nearati P
Phytother Res; 2015 May; 29(5):701-6. PubMed ID: 25624269
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetics of desipramine metabolism.
Musa MN; Miescke KJ
Int J Clin Pharmacol Ther; 1994 Mar; 32(3):126-30. PubMed ID: 8205373
[TBL] [Abstract][Full Text] [Related]
37. Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies.
Kozisek ME; Deupree JD; Burke WJ; Bylund DB
J Neurosci Methods; 2007 Jun; 163(1):83-91. PubMed ID: 17400296
[TBL] [Abstract][Full Text] [Related]
38. Saliva and plasma desipramine levels in Asian and Caucasian volunteers.
Pi EH; Tran-Johnson TK; Gray GE; Walker NR; Suckow RF; Cooper TB
Psychopharmacol Bull; 1991; 27(3):281-4. PubMed ID: 1775599
[TBL] [Abstract][Full Text] [Related]
39. The effect of carbamazepine on valproic acid disposition in adult volunteers.
Panesar SK; Orr JM; Farrell K; Burton RW; Kassahun K; Abbott FS
Br J Clin Pharmacol; 1989 Mar; 27(3):323-8. PubMed ID: 2497766
[TBL] [Abstract][Full Text] [Related]
40. Clinical implications of 2-hydroxydesipramine plasma concentrations.
Nelson JC; Bock JL; Jatlow PI
Clin Pharmacol Ther; 1983 Feb; 33(2):183-9. PubMed ID: 6822031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
